banco bitcoins Top Knowledge

The Chinese medicine sector collectively pulled up Panlong Pharmaceutical's linear daily limit, Panlong Pharmaceutical's linear daily limit, Xiangxue Pharmaceutical, Kunyao Group, Huasen Pharmaceutical, Jingxin Pharmaceutical, Xinguang Pharmaceutical and Changyao Holdings followed suit.New Oriental acquired Taimei International Travel Service. Tianyancha App shows that recently, Taimei (Beijing) International Travel Service Co., Ltd. has undergone industrial and commercial changes, and Tianjin Vision Contemporary Technology Co., Ltd., the original wholly-owned shareholder, has withdrawn, and Beijing New Oriental Wokaide International Education Travel Co., Ltd. has been added as a shareholder and wholly owned. At the same time, the legal representative and several key personnel have changed. Taimei (Beijing) International Travel Service Co., Ltd. was established in May 2016. Its legal representative is Longhua with a registered capital of RMB 5 million. Its business scope covers domestic tourism business, inbound tourism business, outbound tourism business, exhibition activities, conference services, ticketing agents and air ticket sales agents.Backbone Technology: The holding subsidiary recently signed a strategic cooperation agreement on intelligent robots. Backbone Technology (002779) said on the interactive platform on December 12 that recently, Jiangsu Jianmi, the holding subsidiary of the company, signed strategic cooperation agreements with Dongsheng Zhilian and Nanjing Ji Rong respectively, working together to develop and apply automation, visualization and intelligent robots, and promoting the application and development of intelligent technologies in a wider range of fields. Jiangsu Jianmi's Lingrui P1 quadruped robot dog can be used for industrial park management, fire control and public security, daily inspection of power grid and electric power, and inspection of special operation scenes such as smelting enterprises and hazardous chemicals.

Actually, Zhijia has set up a new company to sell new energy vehicles. The enterprise search APP shows that recently, Beijing Dongwo Retail Co., Ltd. was established, with the legal representative of Li Jie and the registered capital of 10 million yuan. Its business scope includes: automobile sales; New energy vehicle sales; Wholesale of auto parts; Sales of electrical accessories for new energy vehicles; Sales of power exchange facilities for new energy vehicles. Enterprise investigation shows that the company is indirectly wholly-owned by Juran Zhijia.The ethylene plant of ExxonMobil Huizhou Ethylene Phase I Project entered the commissioning stage, and ExxonMobil China announced that in December 2024, the 1.6 million tons ethylene plant of ExxonMobil Huizhou Ethylene Phase I Project was handed over to China and entered the commissioning stage in an all-round way. ExxonMobil Huizhou Ethylene Project is located in Huizhou Daya Bay Petrochemical Park. The first phase of the project mainly includes ethylene plants, high-end polyethylene and polypropylene production plants in the middle and lower reaches, and supporting utilities, docks, storage and transportation and environmental protection facilities.Actually, Zhijia has set up a new company to sell new energy vehicles. The enterprise search APP shows that recently, Beijing Dongwo Retail Co., Ltd. was established, with the legal representative of Li Jie and the registered capital of 10 million yuan. Its business scope includes: automobile sales; New energy vehicle sales; Wholesale of auto parts; Sales of electrical accessories for new energy vehicles; Sales of power exchange facilities for new energy vehicles. Enterprise investigation shows that the company is indirectly wholly-owned by Juran Zhijia.

Survey: More than 40% of analysts expect the Bank of Japan to raise interest rates this month, but most think that January next year is the best time. According to the latest survey, observers of the Bank of Japan predict that January is the most likely time to raise interest rates next time, but more than 40% of the respondents still expect to take action next week. According to the survey, about 52% of the 52 economists surveyed expect the Bank of Japan to raise the policy interest rate from 0.25% in January, compared with 32% in the last survey. About 44% of the respondents expect the central bank to take action at the end of the two-day meeting on December 19, down from 53% in the last survey. The survey results show that observers believe that the Bank of Japan's policy meeting this month is likely to move or not to move to a large extent. About 88% of the respondents said that the earliest possible time to raise interest rates in their risk scenarios is next week. Another equally high data shows that Japan's economic and price environment will justify raising interest rates this month.The person in charge of public relations of Extreme Vietnam responded to the operating conditions, saying that the company had no money. Xu Jiye, the person in charge of public relations of Extreme Vietnam Automobile, responded to the financial difficulties of the company, saying that the company needed to find funds to survive because of lack of money. Xu Jiye stressed that he joined the company because he was optimistic about the products, and even bought one without receiving a salary, and recommended it to relatives and friends. He angrily refuted the remarks that the company's difficulties questioned the quality of products and said that he would continue to promote the cause of autonomous driving.The next "explosion point" of biomedicine may appear in Shenzhen. "China's pharmaceutical innovation ranks first in the second echelon in the world in terms of the quantitative indicators of R&D pipelines and listed new drugs." A few days ago, Song Ruilin, executive president of China Pharmaceutical Innovation Promotion Association, held the "Star of the Bay Area" biomedical source innovation conference in Shenzhen, and believed that China's pharmaceutical research and industrial development were entering a new stage of innovation. Chen Qiyu, vice president of China Pharmaceutical Innovation Promotion Association and executive director and co-CEO of Fosun International, said that Shenzhen has great advantages and development momentum in linking Greater Bay Area's urban development and AI technology. By leveraging the resources in the Bay Area and making good use of these advantages, it is possible to find a new fulcrum in the future biomedical R&D innovation track, and the next "explosion point" of biomedicine is likely to appear in Shenzhen.